Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK-1169 vs Ceftazidime-Avibactam in HABP/VABP
NCT07634198Phase 3Not yet recruiting
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Apr 2028
01
Overview
Phase 3, randomised, double-blind trial of cefepime + avibactam in hospital-acquired bacterial pneumonia (HAP) and ventilator-associated pneumonia (VAP) (2 arms), sponsored by Nanjing Yoko Biomedical Co., Ltd. Primary endpoint: All-cause mortality at 28 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cefepime + avibactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07634198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634198.